Fast Five Quiz: HER2+ Breast Cancer

Pavani Chalasani, MD, MPH


August 23, 2022

According to the NCCN Clinical Practice Guidelines for Breast Cancer for the management of invasive breast cancer, pertuzumab plus trastuzumab plus docetaxel is a preferred systemic therapy regimen for recurrent unresectable or stage IV HER2+ breast cancer (category 1 recommendation). Pertuzumab plus trastuzumab plus paclitaxel is also listed as a preferred regimen (category 2A recommendation).

For additional information, refer to European Society of Medical Oncology (ESMO) Metastatic Breast Cancer Living Guidelines for the treatment of patients with HER2+ metastatic breast cancer.

Learn more about the treatment of HER2+ breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.